Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961331 · ClinicalTrials.gov registry record
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 86
- Enrollment target
NCT06961331 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 86 participants.
The verdict
NCT06961331 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet therapy immediately following T-DXd therapy in patients diagnosed with HER2+ metastatic breast cancer (mBC) in the United States.
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Tucatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2025-09-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961331
The ClinicalTrials.gov registry entry for NCT06961331 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT06961331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06961331 about?
NCT06961331 is a clinical study titled "Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.". A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet ther...
What is the current status of trial NCT06961331?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2025-05-07. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT06961331?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Tucatinib (DRUG).
Who is sponsoring clinical trial NCT06961331?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.